Please login to the form below

Not currently logged in


This page shows the latest Takhzyro news and features for those working in and with pharma, biotech and healthcare.

Takeda’s HAE drug Takhzyro backed by NICE

Takeda’s HAE drug Takhzyro backed by NICE

Like Firazyr and Cinryze, Takhzyro was originally developed by Shire, which has been absorbed by Takeda in a  $63bn takeover. ... Analysts have predicted that Takhzyro could make up to $2bn in peak sales.

Latest news

More from news
Approximately 4 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Analysts at Bernstein recently predicted that Takhzyro will eventually dominate the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...